article
Issue #4 2016 – Digital edition
In this issue: Regulation, Environmental Monitoring, Drug Delivery; Microbiology, Track & race, Spectroscopy, HPLC, Mass Spectrometry, and much more...
List view / Grid view
Issue 4 2016
article
The legal framework applicable to biosimilars in the EU
Biosimilars are becoming increasingly important in the European Union’s biopharmaceutical landscape due to the increased growth of biologicals as key therapies and the financial pressure this puts on healthcare budgets.
article
Environmental Monitoring In-Depth Focus 2016
24 August 2016 | By European Pharmaceutical Review
In this Environmental Monitoring In-Depth Focus: Bacterial endotoxin contamination and testing limits in ophthalmics; The basics of environmental monitoring in aseptic units; Environmental Monitoring Roundtable...
article
Spectroscopy In-Depth Focus 2016
In this Spectroscopy In-Depth Focus: The benefits of NIRS in monitoring and controlling a crystallisation process; Pharmaceutical applications of terahertz spectroscopy and imaging; and much more...
article
Approaches in subcutaneous delivery of monoclonal antibodies
Currently, subcutaneous delivery of therapeutic proteins is a fast-growing field, especially for such established modalities as monoclonal antibodies, which require large quantities of drug to be administrated. Different approaches, including high protein concentration, speciality formulations and drug delivery matrices, as well as devices enabling a more rapid administration of larger…
article
Current activities of the USP general chapters
From a microbiological perspective, pharmaceutical products fall into two categories – nonsterile and sterile. For both categories manufacturers must eliminate, or minimise, potential health risks to patients related to microorganisms and the toxins they produce, whilst maintaining product quality. Many contributing factors may affect the quality of a medicine or…
article
Application of LCMS in small-molecule drug development
As a technology, mass spectrometry (MS) has evolved to the point where it is used throughout the drug development process. In particular, when MS is coupled with high-performance liquid chromatography (HPLC) it adds an orthogonal detection function for sample analysis and provides unique capabilities for pharmaceutical analysis, such as sensitivity,…
article
Characterising therapeutic antibodies and ADCs using mass spectrometry
Since the 1970s, the advent of biotechnology has resulted in the development and commercialisation of many therapeutic proteins, including antibodies and antibody fragments, for the treatment of human diseases. Examples include antibody treatments for autoimmune diseases (for example, adalimumab [Humira®] for rheumatoid arthritis), cancers (such as trastuzumab [Herceptin®] for breast…
